FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014906239> ?p ?o ?g. }

• W3014906239 endingPage "309" @default.
• W3014906239 startingPage "301" @default.
• W3014906239 abstract "The Maastricht V Consensus recommends quadruple therapies as first-line Helicobacter pylori treatment in high clarithromycin (CLA) resistance areas. To compare efficacy, side effects and compliance between quadruple concomitant non-bismuth vs bismuth quadruple therapy. Prospective study enrolling H. pylori-positive patients. Omeprazol and a three-in-one formulation of bismuth–metronidazol–tetracycline (OBMT-3/1) for 10 days, or combination of omeprazol–clarithromycin–amoxicillin–metronidazol (OCAM) for 14 days, were prescribed. Eradication outcome was assessed by urea breath test or histology. Side effects and compliance were recorded during the treatment period with specific questionnaires. 404 patients were recruited (median age 53 years; 62.87% women). In 382 (183 with OCAM, 199 with OBMT-3/1) the post-treatment test result was available. The eradication rates were 85.94% (CI95%: 80.20–90.52) with OCAM and 88.21% (CI95%: 83.09–92.22) with OBMT-3/1 (p = 0.595) in intention-to-treat analysis, whilst in per protocol analysis they were 91.12% (CI95%: 85.78–94.95) and 96.17% (CI95%: 92.28–98.45) respectively (p = 0.083). Compliance over 90% was 91.35% with OCAM and 92.04% with OBMT-3/1 (p = 0.951). Some side effect was present in 94.02% with OCAM and in 88.89% with OBMT-3/1 (p = 0.109), being longer (12 vs 7 days, p < 0.0001) and more severe (p < 0.0001) with OCAM. In a high CLA-resistance area, there are no differences between OBMT-3/1 and OCAM in H. pylori eradication and compliance rates, but OBMT-3/1 achieves a higher safety profile. El Consenso de Maastricht V recomienda tetraterapias como tratamiento de primera línea de Helicobacter pylori en áreas con elevada resistencia a claritromicina (CLA). Comparar la eficacia, los efectos secundarios y el cumplimiento terapéutico entre la tetraterapia sin bismuto y la tetraterapia con bismuto. Estudio prospectivo que incluyó a pacientes con H. pylori. Se prescribió omeprazol y una formulación 3 en uno de bismuto-metronidazol-tetraciclina (OBMT-3/1) durante 10 días, o una combinación de omeprazol-claritromicina-amoxicilina-metronidazol (OCAM) durante 14 días. El resultado de la erradicación se evaluó mediante una prueba de aliento con urea o histología. Los efectos secundarios y el cumplimiento terapéutico se registraron durante el período de tratamiento empleando cuestionarios específicos. Se incluyeron 404 pacientes (mediana de edad de 53 años; un 62,87% de mujeres). El resultado de la prueba posterior al tratamiento estuvo disponible en 382 pacientes (183 con OCAM, 199 con OBMT-3/1). Las tasas de erradicación fueron del 85,94% (IC 95%: 80,20-90,52) con OCAM y del 88,21% (IC 95%: 83,09-92,22) con OBMT-3/1 (p = 0,595) en el análisis por intención de tratar, mientras que en el análisis por protocolo fueron del 91,12% (IC 95%: 85,78-94,95) y del 96,17% (IC 95%: 92,28-98,45), respectivamente (p = 0,083). El cumplimiento terapéutico superior al 90% fue del 91,35% con OCAM y del 92,04% con OBMT-3/1 (p = 0,951). Se observaron efectos secundarios en el 94,02% de los pacientes tratados con OCAM y en el 88,89% de los tratados con OBMT-3/1 (p = 0,109), y fueron más prolongados (12 frente a 7 días, p < 0,0001) y más graves (p < 0,0001) con OCAM. En un área con elevada resistencia a la CLA no se observan diferencias entre OBMT-3/1 y OCAM en la erradicación de H. pylori ni en las tasas de cumplimiento, pero OBMT-3/1 presenta un perfil de seguridad superior." @default.
• W3014906239 created "2020-04-10" @default.
• W3014906239 creator A5019463861 @default.
• W3014906239 creator A5020734591 @default.
• W3014906239 creator A5042424178 @default.
• W3014906239 creator A5045314648 @default.
• W3014906239 creator A5054930612 @default.
• W3014906239 creator A5061159416 @default.
• W3014906239 creator A5065389922 @default.
• W3014906239 creator A5078431511 @default.
• W3014906239 creator A5079379679 @default.
• W3014906239 date "2020-06-01" @default.
• W3014906239 modified "2023-09-23" @default.
• W3014906239 title "Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy" @default.
• W3014906239 cites W1189719029 @default.
• W3014906239 cites W1556376361 @default.
• W3014906239 cites W1583062921 @default.
• W3014906239 cites W1676834274 @default.
• W3014906239 cites W1826619807 @default.
• W3014906239 cites W1883517927 @default.
• W3014906239 cites W1971782748 @default.
• W3014906239 cites W2048487294 @default.
• W3014906239 cites W2080089323 @default.
• W3014906239 cites W2082993930 @default.
• W3014906239 cites W2116916903 @default.
• W3014906239 cites W2158819521 @default.
• W3014906239 cites W2165886643 @default.
• W3014906239 cites W2199203801 @default.
• W3014906239 cites W2199230185 @default.
• W3014906239 cites W2415786957 @default.
• W3014906239 cites W2527848138 @default.
• W3014906239 cites W2570938003 @default.
• W3014906239 cites W2585512031 @default.
• W3014906239 cites W2746987056 @default.
• W3014906239 cites W2766822484 @default.
• W3014906239 cites W2793923874 @default.
• W3014906239 cites W2801555073 @default.
• W3014906239 cites W2809070540 @default.
• W3014906239 cites W2875993675 @default.
• W3014906239 cites W2881320234 @default.
• W3014906239 cites W2887218522 @default.
• W3014906239 cites W2896159478 @default.
• W3014906239 cites W2963949738 @default.
• W3014906239 doi "https://doi.org/10.1016/j.gastrohep.2019.12.002" @default.
• W3014906239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32253018" @default.
• W3014906239 hasPublicationYear "2020" @default.
• W3014906239 type Work @default.
• W3014906239 sameAs 3014906239 @default.
• W3014906239 citedByCount "6" @default.
• W3014906239 countsByYear W30149062392020 @default.
• W3014906239 countsByYear W30149062392022 @default.
• W3014906239 crossrefType "journal-article" @default.
• W3014906239 hasAuthorship W3014906239A5019463861 @default.
• W3014906239 hasAuthorship W3014906239A5020734591 @default.
• W3014906239 hasAuthorship W3014906239A5042424178 @default.
• W3014906239 hasAuthorship W3014906239A5045314648 @default.
• W3014906239 hasAuthorship W3014906239A5054930612 @default.
• W3014906239 hasAuthorship W3014906239A5061159416 @default.
• W3014906239 hasAuthorship W3014906239A5065389922 @default.
• W3014906239 hasAuthorship W3014906239A5078431511 @default.
• W3014906239 hasAuthorship W3014906239A5079379679 @default.
• W3014906239 hasConcept C126322002 @default.
• W3014906239 hasConcept C178790620 @default.
• W3014906239 hasConcept C185592680 @default.
• W3014906239 hasConcept C188816634 @default.
• W3014906239 hasConcept C2775981797 @default.
• W3014906239 hasConcept C2776409635 @default.
• W3014906239 hasConcept C2776962512 @default.
• W3014906239 hasConcept C2777172195 @default.
• W3014906239 hasConcept C2778204628 @default.
• W3014906239 hasConcept C2779116819 @default.
• W3014906239 hasConcept C2779384505 @default.
• W3014906239 hasConcept C2779708577 @default.
• W3014906239 hasConcept C2908868296 @default.
• W3014906239 hasConcept C501593827 @default.
• W3014906239 hasConcept C533668322 @default.
• W3014906239 hasConcept C71924100 @default.
• W3014906239 hasConcept C86803240 @default.
• W3014906239 hasConcept C89423630 @default.
• W3014906239 hasConcept C90924648 @default.
• W3014906239 hasConceptScore W3014906239C126322002 @default.
• W3014906239 hasConceptScore W3014906239C178790620 @default.
• W3014906239 hasConceptScore W3014906239C185592680 @default.
• W3014906239 hasConceptScore W3014906239C188816634 @default.
• W3014906239 hasConceptScore W3014906239C2775981797 @default.
• W3014906239 hasConceptScore W3014906239C2776409635 @default.
• W3014906239 hasConceptScore W3014906239C2776962512 @default.
• W3014906239 hasConceptScore W3014906239C2777172195 @default.
• W3014906239 hasConceptScore W3014906239C2778204628 @default.
• W3014906239 hasConceptScore W3014906239C2779116819 @default.
• W3014906239 hasConceptScore W3014906239C2779384505 @default.
• W3014906239 hasConceptScore W3014906239C2779708577 @default.
• W3014906239 hasConceptScore W3014906239C2908868296 @default.
• W3014906239 hasConceptScore W3014906239C501593827 @default.
• W3014906239 hasConceptScore W3014906239C533668322 @default.
• W3014906239 hasConceptScore W3014906239C71924100 @default.
• W3014906239 hasConceptScore W3014906239C86803240 @default.
• W3014906239 hasConceptScore W3014906239C89423630 @default.

• next